Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease.

Veening-Griffioen DH, Ferreira GS, van Meer PJK, Boon WPC, Gispen-de Wied CC, Moors EHM, Schellekens H.

Eur J Pharmacol. 2019 Jul 7;859:172524. doi: 10.1016/j.ejphar.2019.172524. [Epub ahead of print]

PMID:
31291566
2.

A standardised framework to identify optimal animal models for efficacy assessment in drug development.

S Ferreira G, Veening-Griffioen DH, Boon WPC, Moors EHM, Gispen-de Wied CC, Schellekens H, van Meer PJK.

PLoS One. 2019 Jun 13;14(6):e0218014. doi: 10.1371/journal.pone.0218014. eCollection 2019.

3.

Baseline imbalances and clinical outcomes of atypical antipsychotics in dementia: A meta-epidemiological study of randomized trials.

Hulshof TA, Zuidema SU, van Meer PJK, Gispen-de Wied CC, Luijendijk HJ.

Int J Methods Psychiatr Res. 2019 Mar;28(1):e1757. doi: 10.1002/mpr.1757. Epub 2018 Dec 4.

4.

The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals.

van Meer PJ, Graham ML, Schuurman HJ.

Eur J Pharmacol. 2015 Jul 15;759:3-13. doi: 10.1016/j.ejphar.2015.02.055. Epub 2015 Mar 27. Review.

PMID:
25818943
5.

Contribution of animal studies to evaluate the similarity of biosimilars to reference products.

van Meer PJ, Ebbers HC, Kooijman M, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H.

Drug Discov Today. 2015 Apr;20(4):483-90. doi: 10.1016/j.drudis.2014.11.009. Epub 2014 Nov 20. Review.

PMID:
25463036
6.

The value of non-human primates in the development of monoclonal antibodies.

van Meer PJ, Kooijman M, van der Laan JW, Moors EH, Schellekens H.

Nat Biotechnol. 2013 Oct;31(10):882-3. doi: 10.1038/nbt.2709. No abstract available.

PMID:
24104750
7.

The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies.

Kooijman M, van Meer PJ, Gispen-de Wied CC, Moors EH, Hekkert MP, Schellekens H.

Regul Toxicol Pharmacol. 2013 Nov;67(2):221-5. doi: 10.1016/j.yrtph.2013.07.014. Epub 2013 Aug 7.

PMID:
23933031
8.

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.

van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H.

MAbs. 2013 Sep-Oct;5(5):810-6. doi: 10.4161/mabs.25234. Epub 2013 Jun 6.

9.

Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.

Ebbers HC, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, Schellekens H.

Drug Discov Today. 2013 Sep;18(17-18):872-9. doi: 10.1016/j.drudis.2013.05.004. Epub 2013 May 18. Review.

PMID:
23688584
10.

The ability of animal studies to detect serious post marketing adverse events is limited.

van Meer PJ, Kooijman M, Gispen-de Wied CC, Moors EH, Schellekens H.

Regul Toxicol Pharmacol. 2012 Dec;64(3):345-9. doi: 10.1016/j.yrtph.2012.09.002. Epub 2012 Sep 12.

PMID:
22982732
11.

Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?

Kooijman M, van Meer PJ, Moors EH, Schellekens H.

Expert Opin Drug Saf. 2012 Sep;11(5):797-801. doi: 10.1517/14740338.2012.712110. Epub 2012 Aug 6. Review.

PMID:
22861668
12.

Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Siegel JA, Benice TS, Van Meer P, Park BS, Raber J.

Neurobiol Aging. 2011 Jan;32(1):75-84. doi: 10.1016/j.neurobiolaging.2008.12.006. Epub 2009 Jan 28.

13.

Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain.

Acevedo SF, Pfankuch T, van Meer P, Raber J.

J Neurochem. 2008 Nov;107(4):976-86. doi: 10.1111/j.1471-4159.2008.05673.x. Epub 2008 Sep 11.

14.

Passive avoidance learning and memory of 56Fe sham-irradiated and irradiated human apoE transgenic mice.

Villasana L, Poage C, van Meer P, Raber J.

Radiats Biol Radioecol. 2008 Mar-Apr;48(2):167-70.

PMID:
18666648
15.

An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity.

Bongers G, Krueger KM, Miller TR, Baranowski JL, Estvander BR, Witte DG, Strakhova MI, van Meer P, Bakker RA, Cowart MD, Hancock AA, Esbenshade TA, Leurs R.

J Pharmacol Exp Ther. 2007 Dec;323(3):888-98. Epub 2007 Sep 12.

PMID:
17855474
16.

Reduced histamine levels and H3 receptor antagonist-induced histamine release in the amygdala of Apoe-/- mice.

van Meer P, Pfankuch T, Raber J.

J Neurochem. 2007 Oct;103(1):124-30. Epub 2007 Jun 15.

17.

Impairments in spatial memory retention of GFAP-apoE4 female mice.

van Meer P, Acevedo S, Raber J.

Behav Brain Res. 2007 Jan 25;176(2):372-5. Epub 2006 Nov 28.

18.

Mouse behavioural analysis in systems biology.

Van Meer P, Raber J.

Biochem J. 2005 Aug 1;389(Pt 3):593-610. Review.

Supplemental Content

Loading ...
Support Center